Rapamycin, a novel macrolide immunosuppressive drug, is increasingly used as an agent for post-transplant immunosuppression and treatment of autoimmune disease. Rapamycin inhibits mammalian target of rapamycin resulting in delayed wound healing. This delayed wound healing was normalized by treatment with basic fibroblast growth factor. This indicates that basic fibroblast growth factor plays an important and critical role in the rapamycin-induced delayed wound healing process.
|出版ステータス||Published - 2012 3月|
ASJC Scopus subject areas